Safety of Blood and Plasma Derivatives: Pathogen Reducing Technologies
Human blood and blood products is the source of a wide range of medicinal products used for the treatment and prevention of a variety of injuries and disease. Despite stringent routine measures and filters employed, residual pathogen infectivity remains an important challenge in the field of blood t...
Main Authors: | A. A. Pourfathollah, K. Mousavi Hosseini, M. A. Jalili, Z. Motallebi, H. Rezvan |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2006-07-01
|
Series: | Medical Journal of The Islamic Republic of Iran |
Subjects: | |
Online Access: | http://mjiri.tums.ac.ir/browse.php?a_code=A-10-1-214&slc_lang=en&sid=1 |
Similar Items
-
Pathogen inactivation of blood derived biological medicines: review article
by: Shahnaz Nazari, et al.
Published: (2017-07-01) -
Improving quality of components and protein preparations of blood plasma by introduction of quality management according to the principles of GMP and ISO 9001 in the blood service institutions with benchmarking effectiveness
by: Liubchack V.V., et al.
Published: (2014-09-01) -
Inactivation and Environmental Stability of Zika Virus
by: Janis A. Müller, et al.
Published: (2016-09-01) -
Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
by: Changzhong Jin, et al.
Published: (2021-04-01) -
New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods
by: Galli Luca, et al.
Published: (2020-04-01)